Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29%

Commodore Capital reduced its Nuvalent stake by 850,000 shares in the fourth quarter; the estimated trade size was $83.81 million based on quarterly average pricing. Meanwhile, the quarter-end position value dropped by $65.75 million, reflecting both share sales and stock price movement.

The Motley Fool • Feb 23, 2026

Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

CAMBRIDGE, Mass., Feb. 5, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D.

PRNewsWire • Feb 5, 2026

3 Biotech Stocks That Could Double In 2026

The biotech sector is one that's become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names in the market, as growth in other sectors of the economy have led to valuations that now look more elevated than the biotech sector (in many cases).

24/7 Wall Street • Jan 20, 2026

Nuvalent, Inc. (NUVL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Nuvalent, Inc. (NUVL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 13, 2026

Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones

FDA accepted NDA for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC; PDUFA target action date of September 18, 2026 NDA submission for neladalkib in TKI pre-treated advanced ALK-positive NSCLC population planned for the first half of 2026 Submission for potential indication expansion of zidesamtinib in TKI-naïve advanced ROS1-positive NSCLC population planned for the second half of 2026 Well capitalized with operating runway anticipated into 2029 Company to present at 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13th at 9:00 a.m.

PRNewsWire • Jan 12, 2026

3 Biotech Stocks With Major 2026 Catalysts

Biotech's 2025 rebound sets the stage for Denali Therapeutics and two peers, with key FDA decisions and pipeline catalysts lined up for 2026.

Zacks Investment Research • Dec 29, 2025

Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. , Dec. 22, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D.

PRNewsWire • Dec 22, 2025

Nuvalent Appoints Ron Squarer to Board of Directors

CAMBRIDGE, Mass. , Dec. 10, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Ron Squarer to its Board of Directors.

PRNewsWire • Dec 10, 2025

Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference

CAMBRIDGE, Mass. , Nov. 26, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D.

PRNewsWire • Nov 26, 2025

Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders

CAMBRIDGE, Mass. , Nov. 24, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the closing of its previously announced underwritten public offering of 4,950,496 shares of Class A common stock at a price to the public of $101.00 per share.

PRNewsWire • Nov 24, 2025